InvestorsHub Logo
Followers 33
Posts 2049
Boards Moderated 0
Alias Born 11/06/2011

Re: GMA13 post# 34232

Tuesday, 10/24/2023 2:02:02 PM

Tuesday, October 24, 2023 2:02:02 PM

Post# of 34618
He replied to my email earlier this month. I inquired about a few things one being the strategic review and for what its worth I received a copy and paste of the answer he provided you a couple months ago. I've probably sent two emails the whole year though. Maybe you are sending too many? He obviously has a lot to do so I'm not surprised some emails go unanswered. My personal opinion is the more you send the more likely they will be ignored. Especially if they contain the same questions over and over again.

As far as major news goes, we already know roughly what to expect by the end of the year.

1. Strategic review. (Barring any delay from the FDA as this is what I believe is holding up the review since it will involve changes to existing trials the FDA needs to approve them. We can't get the update with out that)
2. MRD data.
3. Lymphoma data.
4. Potential pancreatic trial grant. (This doesn't really have a date on it but it was referenced earlier this year)

Anything outside of that would be a surprise and probably unlikely. I also wouldn't consider any of the above major news. We'll see how this all shakes out.

My DD is not a substitute for your DD

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News